Compare FBP & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBP | ARQT |
|---|---|---|
| Founded | 1948 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | N/A | 2020 |
| Metric | FBP | ARQT |
|---|---|---|
| Price | $21.25 | $29.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $23.67 | ★ $24.83 |
| AVG Volume (30 Days) | 1.2M | ★ 2.4M |
| Earning Date | 01-22-2026 | 10-28-2025 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | ★ 13.12 | N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $902,789,000.00 | $317,929,000.00 |
| Revenue This Year | $12.49 | $85.51 |
| Revenue Next Year | $4.57 | $30.74 |
| P/E Ratio | $10.33 | ★ N/A |
| Revenue Growth | 3.91 | ★ 129.21 |
| 52 Week Low | $16.40 | $11.13 |
| 52 Week High | $22.61 | $31.77 |
| Indicator | FBP | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 64.68 | 55.66 |
| Support Level | $20.02 | $28.30 |
| Resistance Level | $21.32 | $31.77 |
| Average True Range (ATR) | 0.42 | 1.08 |
| MACD | 0.18 | -0.44 |
| Stochastic Oscillator | 86.10 | 20.46 |
First BanCorp is a financial holding company. The company's operating segment includes Commercial and Corporate Banking; Mortgage Banking; Consumer (Retail) Banking; Treasury and Investments; United States Operations; and Virgin Islands Operations. It generates maximum revenue from the Consumer (Retail) Banking segment. The Consumer (Retail) Banking segment generates majority revenue, which consists of the Corporation's consumer lending and deposit-taking activities conducted mainly through its branch network and loan centres. Geographically, it derives a majority of revenue from Puerto Rico.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.